HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients.

AbstractBACKGROUND:
Nutritional therapy is used to reduce the adverse events (AEs) of anticancer drugs. Here, we determined whether the amino acids cystine and theanine, which provide substrates for glutathione, attenuated the AEs of S-1 adjuvant chemotherapy.
METHODS:
Patients scheduled to receive S-1 adjuvant chemotherapy were randomized to the C/T or the control groups. The C/T group received 700 mg cystine and 280 mg theanine orally 1 week before the administration of S-1, which then continued for 5 weeks. Each group received S-1 for 4 weeks. Blood sampling was performed and AEs were evaluated (CTCAE ver. 4.0) before and after the administration of S-1. S-1 was discontinued when AEs ≥ grade 2 occurred.
RESULTS:
The incidences of AEs of any grade and those over grade 2 were lower in the C/T group than in the controls. The incidence of diarrhea (G ≥ 2) was significantly less (p < 0.05) in the C/T group (3.1 %) than in the controls (25.8 %). The duration and completion rate of the S-1 adjuvant chemotherapy were significantly longer (p < 0.01) and higher (p < 0.01), respectively, in the C/T group (complete ratio: 75.0 %, duration: 24.8 ± 5.8 days) than in the controls (complete ratio: 35.5 %, duration: 20.0 ± 7.7 days).
CONCLUSIONS:
The oral administration of cystine and theanine attenuated the AEs of S-1 adjuvant chemotherapy and increased the S-1 completion rate, suggesting that cystine and theanine is a useful supportive care for chemotherapy.
AuthorsTakashi Tsuchiya, Hiroshi Honda, Masaya Oikawa, Tetsuya Kakita, Atsushi Oyama, Hidekazu Oishi, Katsuyuki Tochikubo, Takanao Hashimoto, Shigekazu Kurihara, Tetsuro Shibakusa, Takashi Kayahara
JournalInternational journal of clinical oncology (Int J Clin Oncol) Vol. 21 Issue 6 Pg. 1085-1090 (Dec 2016) ISSN: 1437-7772 [Electronic] Japan
PMID27306219 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • Glutamates
  • Protective Agents
  • S 1 (combination)
  • Tegafur
  • Cystine
  • Oxonic Acid
  • theanine
  • Glutathione
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Antimetabolites, Antineoplastic (administration & dosage, adverse effects)
  • Chemotherapy, Adjuvant (adverse effects, methods)
  • Cystine (administration & dosage)
  • Dietary Supplements
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Drug Monitoring
  • Drug-Related Side Effects and Adverse Reactions (etiology, metabolism)
  • Female
  • Gastrointestinal Neoplasms (drug therapy, pathology)
  • Glutamates (administration & dosage)
  • Glutathione (metabolism)
  • Humans
  • Male
  • Middle Aged
  • Oxonic Acid (administration & dosage, adverse effects)
  • Protective Agents (administration & dosage)
  • Tegafur (administration & dosage, adverse effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: